Saturday, February 02, 2008

Apitope Technology: MS vaccine shows promise in Phase I/IIa

Apitope Technology: MS vaccine shows promise in Phase I/IIa
Pharmaceutical Business Review - USA
By Charlotte Mackey Apitope's recently completed Phase I/IIa open label trial of ATC-MS-1467 was designed as a dose-escalation study to assess the vaccine's ...
See all stories on this topic

Stem Cell Therapy For Brain Repair Is The Focus Of The ASNTR 15th Anniversary Meeting
The American Society for Neural Therapy and Repair 15th Annual Meeting will be held May 1-3, 2008 at the Sheraton Sand Key Resort in Clearwater, Florida. The deadline for submitting abstracts is February 1, 2008.

MediciNova's MN-166 Reduces Persistent Black Hole Formation in ...
CNNMoney.com - USA
The analysis showed that MN-166 decreased the formation of black holes (permanent brain lesions believed to indicate the death of nerves in the brain) on ...
See all stories on this topic

Conn's Appoints Michael Poppe As CFO - Update [CONN]
RTT News - Williamsville,NY,USA
The company said that additional data from a double-blind analysis of the first year of treatment from two-year Phase II clinical trial of MN-166 revealed ...
See all stories on this topic

Market Report -- In Play (MNOV)
MSN Money - USA
MediciNova's MN-166 reduces persistent black hole formation in MS patients Co announces additional data from a double-blind analysis of the first year of ...
See all stories on this topic

Kodiak Energy Raises Working Interest In Lucy Property To 80 ...
RTT News - Williamsville,NY,USA
The analysis showed that MN-166 decreased the formation of black holes, or permanent brain lesions that is believed to indicate the death of nerves in the ...
See all stories on this topic

Signaling Networks That Control Neuron Function Mapped By Researchers
In the first large-scale proteomics study of its kind, researchers at the University of California, San Diego (UCSD) School of Medicine have mapped thousands of neuronal proteins to discover how they connect into complex signaling networks that guide neuron function.

Out of the Gate: Acorda Therapeutics
Houston Chronicle - United States
2008 AP NEW YORK — Shares of Acorda Therapeutics Inc. surged Monday after the company reported trial results that showed its drug candidate Fampridine-SR ...
See all stories on this topic

Acorda Shares Get Nice Bump With Positive MS Trial Results
BioWorld Online - Atlanta,GA,USA
By Donna Young Study results showed that Acorda Therapeutics Inc.'s multiple sclerosis drug Fampridine-SR does not increase a patient's risk of developing ...
See all stories on this topic

Acorda Says Drug Study Is Successful
CNNMoney.com - USA
Fampridine-SR is currently being studied in a late-stage clinical trial to evaluate its safety and effectiveness in improving walking ability in people with ...
See all stories on this topic

Acorda Stock Has Heart
Forbes - NY,USA
Acorda Therapeutics (nasdaq: ACOR - news - people ) said its multiple sclerosis drug Fampridine-SR does not raise the risk of heart-related side effects ...
See all stories on this topic

0 Comments:

Post a Comment

Links to this post:

Create a Link

<< Home